
Patrizia Borsotti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10193647/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tumor vascular remodeling by thrombospondin-1 enhances drug delivery and antineoplastic activity. Matrix Biology, 2021, 103-104, 22-36.	3.6	2
2	CCN-Based Therapeutic Peptides Modify Pancreatic Ductal Adenocarcinoma Microenvironment and Decrease Tumor Growth in Combination with Chemotherapy. Cells, 2020, 9, 952.	4.1	23
3	The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2). Angiogenesis, 2019, 22, 133-144.	7.2	37
4	Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanoma. Carcinogenesis, 2019, 40, 303-312.	2.8	28
5	Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMPâ€1 and TIMPâ€2 and tumor thrombospondinâ€1. International Journal of Cancer, 2015, 136, 721-729.	5.1	50
6	Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts. Connective Tissue Research, 2015, 56, 355-363.	2.3	10
7	Thrombospondinâ€1 is part of a Slugâ€independent motility and metastatic program in cutaneous melanoma, in association with <scp>VEGFR</scp> â€1 and <scp>FGF</scp> â€2. Pigment Cell and Melanoma Research, 2015, 28, 73-81.	3.3	45
8	Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. Cancer Chemotherapy and Pharmacology, 2013, 72, 879-887.	2.3	37
9	Inhibition of SIRT2 Potentiates the Anti-motility Activity of Taxanes: Implications for Antineoplastic Combination Therapies. Neoplasia, 2012, 14, 846-IN16.	5.3	28
10	Vascular Disrupting Activity of Tubulin-Binding 1,5-Diaryl-1 <i>H</i> -imidazoles. Journal of Medicinal Chemistry, 2009, 52, 7906-7910.	6.4	65
11	Bioavailability of VEGF in Tumor-Shed Vesicles Depends on Vesicle Burst Induced by Acidic pH. Neoplasia, 2006, 8, 96-103.	5.3	168
12	The Vascular Targeting Property of Paclitaxel Is Enhanced by SU6668, a Receptor Tyrosine Kinase Inhibitor, Causing Apoptosis of Endothelial Cells and Inhibition of Angiogenesis. Clinical Cancer Research, 2006, 12, 1839-1849.	7.0	54
13	Potential Antagonism of Tubulin-Binding Anticancer Agents in Combination Therapies. Clinical Cancer Research, 2005, 11, 2720-2726.	7.0	23
14	Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin. Clinical Cancer Research, 2004, 10, 4813-4821.	7.0	144
15	Antiangiogenic activity of aplidine, a new agent of marine origin. British Journal of Cancer, 2004, 90, 2418-2424.	6.4	82
16	Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia, 2003, 17, 52-59.	7.2	142
17	Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Research, 2003, 63, 1534-7.	0.9	94
18	Shedding of the Matrix Metalloproteinases MMP-2, MMP-9, and MT1-MMP as Membrane Vesicle-Associated Components by Endothelial Cells. American Journal of Pathology, 2002, 160, 673-680.	3.8	502

PATRIZIA BORSOTTI

#	Article	IF	CITATIONS
19	Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clinical Cancer Research, 2002, 8, 1182-8.	7.0	50
20	p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. Oncogene, 2001, 20, 7293-7300.	5.9	51
21	Inhibition of matrix metalloproteinases by overâ€expression of tissue inhibitor of metalloproteinaseâ€2 inhibits the growth of experimental hemangiomas. International Journal of Cancer, 2001, 91, 241-247.	5.1	29
22	Posttranscriptional Stimulation of Endothelial Cell Matrix Metalloproteinases 2 and 1 by Endothelioma Cells. Experimental Cell Research, 2000, 258, 384-394.	2.6	43
23	Endothelin-1 Induces an Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo. American Journal of Pathology, 2000, 157, 1703-1711.	3.8	322
24	Thrombospondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat-induced angiogenesis and is poorly expressed in KS lesions. , 1999, 188, 76-81.		44
25	Effect of alltrans-retinoic acid (ATRA) on the adhesive and motility properties of acute promyelocytic leukemia cells. , 1997, 70, 72-77.		21
26	Inhibition of Angiogenesis and Murine Hemangioma Growth by Batimastat, a Synthetic Inhibitor of Matrix Metalloproteinases. Journal of the National Cancer Institute, 1995, 87, 293-298.	6.3	220